A randomized controlled trial of intensive urate-lowering therapy for bone erosion in tophaceous gout

Phase 4

Completed

• Conditions: gout; Musculoskeletal - Other muscular and skeletal disorders; Metabolic and Endocrine - Other metabolic disorders

• Registration Number: ACTRN12615001219572
• Lead Sponsor: niversity of Auckland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-11-09
• Study Completion: 2020-06-30
• Last Update Posted: 14 June 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

Gout, as defined by the 2015 ACR-EULAR classification criteria
At least one bone erosion on plain radiographs of the feet
Age over 18 years
Able to provide informed consent
On oral urate-lowering therapy
Serum urate concentrations at or above 0.30mmol/L

Exclusion Criteria

Stage 4 or 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) <30mls/min/1.73m2)
Pregnancy or breastfeeding
Unstable systemic medical condition
On azathioprine (due to potential interactions with both allopurinol and febuxostat)
On warfarin

Study & Design

• Study Type: Interventional
• Study Design: Not specified